{"id":"NCT00429923","sponsor":"Sirion Therapeutics, Inc.","briefTitle":"Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)","officialTitle":"A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":null,"primaryCompletion":null,"completion":null,"firstPosted":"2007-02-01","resultsPosted":"2009-07-02","lastUpdate":"2009-07-02"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Inflammation"],"interventions":[{"type":"DRUG","name":"Difluprednate","otherNames":[]},{"type":"DRUG","name":"Difluprednate","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Difluprednate 0.05% BID","type":"EXPERIMENTAL"},{"label":"Difluprednate 0.05% QID","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.","primaryOutcome":{"measure":"Anterior Chamber Cell Grade of \"0\" on Day 8 (Difluprednate QID vs Placebo).","timeFrame":"Day 8 (QID)","effectByArm":[{"arm":"Difluprednate 0.05% BID","deltaMin":0,"sd":null},{"arm":"Difluprednate 0.05% QID","deltaMin":19,"sd":null},{"arm":"Placebo","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.0014"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["19101421"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}